IB3000

IB3000 is an early-stage drug candidate in the pipeline of IntraBio, a biopharmaceutical company focused on developing novel treatments for rare and common neurodegenerative diseases. It is part of a series of developmental programs, including the IB2000, IB4000, and IB5000 series, which complement the company's lead program, IB1001 (N-acetyl-L-leucine). IB3000 is categorized as a small molecule new chemical entity (NCE) and is currently in the discovery or preclinical phase. While IntraBio targets conditions such as Niemann-Pick disease type C, GM2 gangliosidosis, and ataxia-telangiectasia with its more advanced assets, the specific therapeutic indications and molecular targets for IB3000 remain proprietary and have not been publicly disclosed.